Travere Therapeutics, Inc.
TVTXNASDAQHealthcare● Active
$47.54
+$1.73(+3.78%)
Market Cap$4.4B
P/E Ratio—
52W High$48.61
52W Low$13.88
Travere Therapeutics, Inc. (TVTX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · TVTX · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.49B | $0.23B | $0.15B | $0.11B | $0.13B |
| Cost of Revenue | $0.01B | $0.01B | $0.01B | $0.00B | $0.00B |
| Gross Profit | $0.48B | $0.23B | $0.13B | $0.11B | $0.13B |
| Gross Margin %(computed) | 97.89% | 96.68% | 92.12% | 95.96% | 97.10% |
| Operating Expenses | |||||
| R&D Expenses | $0.21B | $0.28B | $0.24B | $0.23B | $0.20B |
| G&A Expenses | $0.34B | $0.26B | $0.27B | $0.20B | $0.13B |
| Total Operating Expenses | $0.54B | $0.55B | $0.52B | $0.42B | $0.33B |
| Operating Income | ($0.06B) | ($0.32B) | ($0.39B) | ($0.32B) | ($0.20B) |
| Operating Margin %(computed) | -12.80% | -138.88% | -267.24% | -292.17% | -151.27% |
| Interest Income | $0.01B | $0.02B | $0.02B | $0.01B | $0.00B |
| Interest Expense | $0.01B | $0.01B | $0.01B | $0.01B | $0.02B |
| Income Before Tax | ($0.05B) | ($0.32B) | ($0.38B) | ($0.33B) | ($0.22B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.03B) | ($0.32B) | ($0.11B) | ($0.28B) | ($0.18B) |
| Net Margin %(computed) | -5.21% | -137.90% | -76.70% | -254.41% | -136.60% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.56 | $-4.08 | $-1.50 | $-4.37 | $-3.01 |
| Wtd Avg Shares | 0.09B | 0.08B | 0.07B | 0.06B | 0.06B |
| EBITDA | $0.02B | ($0.27B) | ($0.33B) | ($0.30B) | ($0.18B) |
| EBITDA Margin %(computed) | 4.53% | -113.98% | -224.63% | -273.54% | -139.91% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Travere Therapeutics, Inc. data
About Travere Therapeutics, Inc. (TVTX) Income Statement
Travere Therapeutics, Inc. (TVTX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, TVTX reported revenue of $0.49B, gross profit of $0.48B (gross margin 97.89%), and net income of ($0.03B) — a net profit margin of -5.21%.
Frequently asked questions
TVTX · 4 questionsTravere Therapeutics, Inc. (TVTX) reported revenue of $0.49B for 2025, up 110.5% year-over-year.
TVTX revenueTVTX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08